Phenylephrine, Long Time On Market For Hypotension, Goes To FDA Panel
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency seeks counsel on whether elevation in blood pressure is sufficient clinical benefit to approve the literature-based NDA for West-Ward Pharmaceutical’s product, which is currently an unapproved drug.
You may also be interested in...
Endpoint Selection Still An Issue For Publication-Based NDAs
FDA’s Cardiovascular and Renal Drugs Advisory Committee Sept. 13 indicated approval for currently marketed phenylephrine to treat hypotension in the peri-operative setting based on the ability to increase blood pressure, but voted 8-2 against its use in shock because of the need for outcomes data.
Sept. 19, 2011: The Day FDA’s Discretion On Unapproved Drugs Stood Still
FDA is drawing a line in the sand when it comes to unapproved drugs, and that line begins at Sept. 19, 2011.
Rx Misbranding Penalties Should Be Stronger To Stop Counterfeiting, FDA Says
Industry also seems supportive of the idea, while Pew touts the power of the power of track-and-trace as a deterrent.